Nanovibronix, Inc. (NASDAQ:FEED) Short Interest Down 61.2% in May

Nanovibronix, Inc. (NASDAQ:FEED) was the recipient of a significant decline in short interest in May. As of May 29th, there was short interest totaling 63,342 shares, a decline of 61.2% from the May 14th total of 163,391 shares. Based on an average daily trading volume, of 280,633 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

FEED has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a research note on Friday, April 24th. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Nanovibronix Price Performance

FEED traded down $0.05 during trading on Friday, reaching $0.83. 459,225 shares of the stock were exchanged, compared to its average volume of 1,769,525. The stock’s 50 day moving average price is $1.23. The firm has a market capitalization of $5.05 million, a P/E ratio of -0.09 and a beta of 1.51. Nanovibronix has a 1 year low of $0.72 and a 1 year high of $17.40.

Nanovibronix (NASDAQ:FEED) last posted its earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. The firm had revenue of $0.65 million for the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.